Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Moving dietary management of diabetes forward.

Kramer H, Chang A.

JAMA Intern Med. 2013 Oct 14;173(18):1692-3. No abstract available.

PMID:
23939227
2.

Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.

Dunkler D, Dehghan M, Teo KK, Heinze G, Gao P, Kohl M, Clase CM, Mann JF, Yusuf S, Oberbauer R; ONTARGET Investigators.

JAMA Intern Med. 2013 Oct 14;173(18):1682-92.

PMID:
23939297
3.

Recent clinical trials.

Gradman AH, Basile JN.

J Am Soc Hypertens. 2014 Oct;8(10):770-4; quiz 775-6. doi: 10.1016/j.jash.2014.08.006. Epub 2014 Aug 15. No abstract available.

PMID:
25418501
4.

[Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].

[No authors listed]

MMW Fortschr Med. 2003 Jun 5;145(23):59. German. No abstract available.

PMID:
12854231
5.

Systolic blood pressure target levels: evidence for benefits in stroke.

Lackland DT.

Hypertension. 2015 Jan;65(1):39-40. doi: 10.1161/HYPERTENSIONAHA.114.04486. Epub 2014 Oct 20. No abstract available.

6.

[Preventing cardiovascular diseases. Discovering the optimal approach].

[No authors listed]

MMW Fortschr Med. 2001 Oct 11;143(41):57. German. No abstract available.

PMID:
11721666
7.

Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).

Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S; ONTARGET Investigators.

J Am Coll Cardiol. 2012 Jan 3;59(1):74-83. doi: 10.1016/j.jacc.2011.09.040.

8.

Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: is less really more?

Budzyn K, Sobey CG, Drummond GR.

J Hypertens. 2010 Jul;28(7):1384-9. doi: 10.1097/HJH.0b013e32833c03fe. No abstract available.

PMID:
20574249
9.

ONTARGET programme of cardio- and vascular protection - first results are imminent.

[No authors listed]

Cardiovasc J Afr. 2008 Jan-Feb;19(1):46-8. No abstract available.

11.

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Metsärinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S; ONTARGET investigators.

Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2.

PMID:
18707986
12.

ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?

Oparil S, Kjeldsen SE, Hedner T, Narkiewicz K.

Blood Press. 2009;18(1-2):4-6. doi: 10.1080/08037050902742282. No abstract available.

PMID:
19191085
13.

[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].

[No authors listed]

MMW Fortschr Med. 2003 Dec 18;145(51-52):39. German. No abstract available.

PMID:
14974331
14.

[Critically appraised article].

Neumann I, Grassi B.

Rev Med Chil. 2012 Jan;140(1):117-20. doi: /S0034-98872012000100018. Epub 2012 Apr 12. Spanish.

15.

Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials.

Böhm M, Baumhäkel M, Teo K, Sleight P, Probstfield J, Gao P, Mann JF, Diaz R, Dagenais GR, Jennings GL, Liu L, Jansky P, Yusuf S; ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators.

Circulation. 2010 Mar 30;121(12):1439-46. doi: 10.1161/CIRCULATIONAHA.109.864199. Epub 2010 Mar 15.

17.

Renal outcome in equipotent antihypertensive treatment with telmisartan, ramipril and in combination in SHR-SP rats.

Schmerbach K, Kalk P, Wengenmayer C, Lucht K, Unger T, Hocher B, Thoene-Reineke C.

Clin Lab. 2012;58(7-8):625-33.

PMID:
22997963
18.

A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET.

Kjeldsen SE, Oparil S, Narkiewicz K, Hedner T.

Blood Press. 2008;17(2):68-9. doi: 10.1080/08037050802117791. No abstract available.

PMID:
18568694
19.

Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.

Yu LT, Zhu J, Tan HQ, Wang GG, Teo KK, Liu LS.

Chin Med J (Engl). 2011 Jun;124(12):1763-8.

PMID:
21740829

Supplemental Content

Support Center